Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

This study is testing a new first-line treatment combination for advanced classic Hodgkin lymphoma (a type of blood cancer): nivolumab (an immunotherapy drug that targets PD-1) combined with the standard AVD chemotherapy regimen (adriamycin, vinblastine, and dacarbazine). The goal is to see if adding nivolumab improves outcomes over chemotherapy alone. **You may be eligible if...** - You are 18 or older with a newly diagnosed and biopsy-confirmed advanced classic Hodgkin lymphoma (stages IIB–IV) - You have not had any previous treatment for this cancer - You have no history of autoimmune disease - Your heart function is adequate (ejection fraction above 50%) **You may NOT be eligible if...** - You have significant organ dysfunction (e.g., kidney, liver failure) - You have an uncontrolled active infection - You are pregnant - You cannot give informed consent Talk to your doctor to see if this trial is right for you.